...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Biochimica et biophysica acta: BBA: International journal of biochemistry, biophysics and molecular biololgy. Proteins and Proteomics >Type 2 diabetes - Therapy with dipeptidyl peptidase IV inhibitors
【24h】

Type 2 diabetes - Therapy with dipeptidyl peptidase IV inhibitors

机译：2型糖尿病-用二肽基肽酶IV抑制剂治疗

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The sole application of an inhibitor of the dipeptidyl peptidase DP IV (also DP 4, CD26, DPP-IV` or DPP-4) to a mammal subsequently leading to improved glucose tolerance marks a major breakthrough in metabolic research bearing the potential of a new revolutionary diabetes therapy. This was demonstrated in rat applying the specific DP IV inhibitor isoleucyl thiazolidine. It was published in 1996 for the first time that a specific DP IV inhibitor in a given dose was able to completely block glucagon-like peptide-1 (GLP- 1) degradation in vivo resulting in improved insulin response accompanied, by accelerated peripheral glucose disposal. Later on, these results were confirmed by several research teams applying DP IV inhibitors intravenously or orally. Today, the DP IV inhibition for the treatment of metabolic disorders is a validated principle. Now, more than 10 years after the initial animal experiments, first DP IV inhibitors as investigational drugs are tested in phase 3 clinical trials. (c) 2005 Published by Elsevier B.V.
机译：二肽基肽酶DP IV（也包括DP 4，CD26，DPP-IV`或DPP-4）抑制剂在哺乳动物上的唯一应用，随后导致葡萄糖耐量的提高，标志着代谢研究的重大突破，具有新的潜力革命性的糖尿病疗法。这在使用特定DP IV抑制剂异亮氨酰噻唑烷的大鼠中得到了证明。 1996年首次发表，给定剂量的特定DP IV抑制剂能够在体内完全阻断胰高血糖素样肽1（GLP-1）的降解，从而改善胰岛素反应，并伴随加速外周葡萄糖处置。后来，一些研究小组通过静脉或口服应用DP IV抑制剂证实了这些结果。如今，DP IV抑制疗法可治疗代谢性疾病，这已成为公认的原理。现在，在最初的动物实验后超过10年的时间里，首批DP IV抑制剂作为研究药物在3期临床试验中进行了测试。 （c）2005年由Elsevier B.V.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号